Vol. 2 No. 1 (2022)
Reimbursement Recommendations

Enfortumab Vedotin (Padcev)

Published January 24, 2022

Key Messages

  • CADTH recommends that Padcev should be reimbursed by public drug plans for the treatment of advanced or metastatic urothelial cancer (UC) if certain conditions are met.
  • Padcev should only be covered to treat adult patients with UC who have already received treatment with a platinum-containing chemotherapy regimen, and a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor for advanced or metastatic disease.
  • Padcev should only be reimbursed if prescribed as monotherapy by a clinician who has experience treating patients with advanced UC and if the price of Padcev is reduced.